 |
SEOUL, South Korea, Oct. 29, 2026 /PRNewswire/ — Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company’s vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), highlighting how pharmaceutical research and development can create new opportunities across both markets.
Speaking during a panel discussion titled “One Pipeline, Two Markets: Dual Commercialization Strategies Through Animal Health,” Robert explored how pharmaceutical companies can leverage their existing technologies, scientific expertise, and drug development capabilities to pursue opportunities in both human and veterinary medicine.
The discussion brought together pharmaceutical and biotechnology leaders to examine emerging business opportunities, regulatory considerations, investment trends, and the potential for global partnerships in animal health.
For Yuyu Pharma, the strategy represents a natural extension of its pharmaceutical heritage. Founded in 1941, Yuyu has spent 85 years building expertise in pharmaceuticals and healthcare. Today, the company is exploring new growth opportunities in biotechnology, animal health, and emerging drug development technologies.
The “One Pipeline, Two Markets” approach recognizes that certain technologies and scientific insights developed for human medicine may also have applications in veterinary medicine. Conversely, research conducted in animal health may generate valuable insights that inform future human drug discovery and development.
“Companion animal pharmaceuticals offer an opportunity to build additional experience and capabilities in drug development,” said Robert. “We believe that scientific insights gained through veterinary drug development may also contribute to future research in human medicine.”
Robert also emphasized the importance of the One Health perspective, which recognizes the connections among human, animal, and environmental health.
“Human and animal health are more closely connected than we often realize,” Robert added. “Our long-term vision is to explore how innovation can move in both directions — from human medicine to animal health, and potentially from animal health back to human medicine.”
As the global companion animal healthcare market continues to evolve, advances in biotechnology, drug delivery, and pharmaceutical research are creating new opportunities for companies with experience in human medicine.
Yuyu Pharma sees animal health as an opportunity to apply its existing pharmaceutical capabilities in a new market while building knowledge, partnerships, and development experience that may support future innovation. For an 85-year-old pharmaceutical company, the strategy reflects a broader commitment to exploring new technologies, entering new markets, and finding new ways to improve health.
About Yuyu Pharma
Founded in 1941, Yuyu Pharma (KRX: 000220) is a South Korean pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceuticals and healthcare products.
Building on 85 years of experience, Yuyu continues to explore new opportunities in biotechnology, animal health, and emerging healthcare businesses through initiatives including Yuyu Bio and Yuyu Venture Studio.
